This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsClearmind Medicine (CMND) 주식 개요A clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. 자세히 보기CMND 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6위험 분석지난 5년간 매년 수익이 66.1% 감소했습니다.의미 있는 시가총액이 없습니다(CA$5M)수익이 USD$1m 미만입니다($0)지난 1년 동안 주주가 크게 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기CMND Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW499,625 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG499,625 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$1.60해당 없음내재 할인율Est. Revenue$PastFuture-9m12016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesClearmind Medicine Inc. 경쟁사Herbal DispatchSymbol: CNSX:HERBMarket cap: CA$6.2mChristina Lake CannabisSymbol: CNSX:CLCMarket cap: CA$6.2mBlueberries MedicalSymbol: CNSX:BBMMarket cap: CA$5.0mAyurcann HoldingsSymbol: CNSX:AYURMarket cap: CA$1.9m가격 이력 및 성과Clearmind Medicine 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$1.6052주 최고가CA$141.0052주 최저가CA$1.25베타1.561개월 변동-16.23%3개월 변동-55.80%1년 변동-98.79%3년 변동n/a5년 변동-98.31%IPO 이후 변동-98.81%최근 뉴스 및 업데이트공시 • Jan 06Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentClearmind Medicine Inc. announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind's successful collaboration with SciSparc Ltd. ("SciSparc"), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-AcylethanOLamines family, including Palmitoylethanolamide.공시 • Jan 02Clearmind Medicine Inc. Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeClearmind Medicine Inc. announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, Hong Kong and now Macau.공시 • Dec 25Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical TrialClearmind Medicine Inc. announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100. The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline.공시 • Nov 21Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025.공시 • Sep 17Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyClearmind Medicine Inc. announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).공시 • Aug 30+ 1 more updateClearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination TreatmentClearmind Medicine Inc. announced the publication of its patent application under the international Patent Cooperation Treaty ("PCT") for innovative combinations of Ketamine and N-Acylethanolamines. The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. ("SciSparc"), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders. As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc's Palmitoylethanolamide ("PEA") with Clearmind's innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions, promoting weight loss and addressing mental health disorders. Furthermore, the two companies are jointly exploring new treatments based on different psychedelic molecules and PEA. To date, 13 patents related to this collaboration have been filled with the U.S. Patent and Trademark Office, as well as several other global jurisdictions. In 2019, the U.S. Food & Drug Administration (the "FDA") approved a ketamine derivative as a nasal spray medication for use in adult patients. It is specifically intended to treat depression in patients that have not responded to other treatments and to alleviate depressive symptoms in individuals with major depressive disorder (MDD) who are experiencing suicidal thoughts or exhibiting suicidal behavior. The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur. Ketamine was approved by the FDA for use under close supervision due to its associated side effects, including the risk of abuse and psychological as well as physical dependence. The ultimate goal is to provide patients with safe and effective treatments that offer t therapeutic benefits, while minimizing adverse effects. The company believe that the collaboration with SciSparc could lead to such solutions.더 많은 업데이트 보기Recent updates공시 • Jan 06Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentClearmind Medicine Inc. announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind's successful collaboration with SciSparc Ltd. ("SciSparc"), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-AcylethanOLamines family, including Palmitoylethanolamide.공시 • Jan 02Clearmind Medicine Inc. Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeClearmind Medicine Inc. announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, Hong Kong and now Macau.공시 • Dec 25Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical TrialClearmind Medicine Inc. announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100. The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline.공시 • Nov 21Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025.공시 • Sep 17Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyClearmind Medicine Inc. announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).공시 • Aug 30+ 1 more updateClearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination TreatmentClearmind Medicine Inc. announced the publication of its patent application under the international Patent Cooperation Treaty ("PCT") for innovative combinations of Ketamine and N-Acylethanolamines. The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. ("SciSparc"), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders. As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc's Palmitoylethanolamide ("PEA") with Clearmind's innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions, promoting weight loss and addressing mental health disorders. Furthermore, the two companies are jointly exploring new treatments based on different psychedelic molecules and PEA. To date, 13 patents related to this collaboration have been filled with the U.S. Patent and Trademark Office, as well as several other global jurisdictions. In 2019, the U.S. Food & Drug Administration (the "FDA") approved a ketamine derivative as a nasal spray medication for use in adult patients. It is specifically intended to treat depression in patients that have not responded to other treatments and to alleviate depressive symptoms in individuals with major depressive disorder (MDD) who are experiencing suicidal thoughts or exhibiting suicidal behavior. The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur. Ketamine was approved by the FDA for use under close supervision due to its associated side effects, including the risk of abuse and psychological as well as physical dependence. The ultimate goal is to provide patients with safe and effective treatments that offer t therapeutic benefits, while minimizing adverse effects. The company believe that the collaboration with SciSparc could lead to such solutions.공시 • Aug 22Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior TreatmentClearmind Medicine Inc. announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program. The approved patent claims cover, among other things, a method of regulating the consumption of alcoholic beverages and a method of controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest patent further bolsters Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India.공시 • Aug 07Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss DrugClearmind Medicine Inc. announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include: Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. Improved Metabolism: MEAI significantly improved glycemic control by reducing hyperglycemia, glucose intolerance and hyperinsulinemia, highlighting its therapeutic potential in regulating glucose metabolism. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation. Increased Energy Expenditure: MEAI increased energy expenditure and fat utilization while maintaining a similar food consumption. Activity: MEAI increased activity-specific energy expenditure without overstimulation supporting its potential to impact energy balance. These findings are based on the results from Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity. This comprehensive study was published in ACS Pharmacology and Translational Science.공시 • Jul 16Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossClearmind Medicine Inc. announced that it has submitted an additional patent application with the United States Patent and Trademark Office ("USPTO"), as part of its ongoing collaborations with SciSparc Ltd. ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with invented with Prof. Joseph Tam from the Hebrew University's technology transfer company, Yissum. The patent application refers to the novel proprietary composition of Clearmind's MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide ("PEA"), the active ingredient of SciSparc's proprietary CannAmide™, for treating metabolic syndrome and obesity. According to the 2017-2020 data from the National Health and Nutrition examination Survey (NHANES) database, the Centers for Disease Control and Prevention (CDC) reported that among adults aged 20 and over, the prevalence of obesity was 41.9%. According to Emergen Research, the global obesity treatment market size was valued at $15 billion in 2022 and is expected to register a rapid revenue CAGR of 10.0% during the forecast period of 2023 to 2032. Rising prevalence of obesity and technological advancements in weight loss equipment are key factors driving market revenue growth. Overall, as part of the collaboration with SciSparc, twelve other patent applications have been filed by Clearmind with the USPTO for various proprietary compositions, including the composition of SciSparc's PEA with Clearmind's MEAI compounds for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.공시 • May 11Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductClearmind Medicine Inc. announced advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed most of the pre-clinical studies required for a novel-food application submission according to novel foods and food additives legislation and regulations accepted in many jurisdictions worldwide. Clearmind’s alcohol substitute was granted patents in the U.S., India and Europe. This project is being led by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, serving as an Executive Special Advisor to the Company.공시 • Apr 10Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersClearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.공시 • Mar 27Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating DepressionClearmind Medicine Inc. announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression. This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”). According to the ResearchAndMarkets.com, the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034. Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s PEA with Clearmind’s MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.공시 • Mar 15Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities ExchangeClearmind Medicine Inc. announced that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on the NASDAQ under the symbol CMND. The company believes that the trading volume of its shares on the CSE no longer justifies the expenses and administrative efforts required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its common shares on the NASDAQ, and ultimately benefit the long-term liquidity and shareholder value of the company. It is anticipated that, effective as at the close of trading on March 14, 2024, Clearmind’s common shares will no longer be listed and posted for trading on the CSE. Following delisting from the CSE, Clearmind’s shareholders can trade their common shares through their brokers on NASDAQ.공시 • Mar 14Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical TrialClearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trial, at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol.공시 • Feb 23Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderClearmind Medicine Inc. announced it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsules. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trials, at theale School of Medicine's Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in Healthy subjects and those with AUD. The secondary endpoint is to evaluate preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol.공시 • Feb 06Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property AdministrationClearmind Medicine Inc. announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company's patent protection around its molecule as well as its extensive IP protection in the psychedelic space. Clearmind's IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India. MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and exerts a slight euphoric, alcohol-like experience with potential to change the lives of millions who struggle to drink in moderation. Clearmind's MEAI-based treatment focuses on Alcohol Use Disorder, which is incredibly common. It varies from mild to excessive and is characterized by a person's inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Clearmind'sMEAI may also be used to treat binge drinking, which can be a deadly addiction for some.공시 • Jan 17Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,500,000 Price\Range: CAD 1.6 Discount Per Security: CAD 0.128 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 1,500,000 Transaction Features: Registered Direct Offering공시 • Jan 11+ 1 more updateClearmind Medicine Inc. has filed a Follow-on Equity Offering.Clearmind Medicine Inc. has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Security Name: Pre-funded Warrants Security Type: Equity Warrant Transaction Features: Registered Direct Offering공시 • Dec 15Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing StandardsClearmind Medicine Inc. announced that on December 12, 2023 it received a formal notification from The Nasdaq Stock Market LLC ('Nasdaq') that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company's common shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed. As a result, the scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel requested by the Company to stay the suspension of the Company’s securities from Nasdaq was canceled. The Company is now in compliance with all applicable listing standards and its common shares will continue to be listed and traded on Nasdaq.공시 • Dec 03Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical TrialSciSparc Ltd. announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine Inc. a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression (the “Combination Treatment”). The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a meaningful degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the Combination Treatment, with the most prominent effects observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.공시 • Nov 29Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based TreatmentClearmind Medicine Inc. announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem. The treatment used in the trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment for various addiction, obesity and metabolic disorders and depression, and SciSparc's Palmitoylethanolamide (PEA), which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide™?. The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that: The administered treatment exhibited a remarkable degree of tolerance., leaving the mice' viability unaffected across all experimental group. Combining MEAI and PEA, especially at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn. A striking reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 u/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.공시 • Nov 18Clearmind Medicine Announces Receipt of Nasdaq Delisting NoticeClearmind Medicine Inc. announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"). The Company was notified that Nasdaq has determined to delist the Company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Company plans to appeal the Staff’s determination to a Hearings Panel (the “Panel”). A hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. As part of the plan to regain compliance with the Minimum Bid Price Rule, the Company intends to conduct a reverse stock split as soon as reasonably practicable, subject to applicable law and Nasdaq rules. On November 14th, the Company’s shareholders approved a reverse stock split, which the Company expects will be made effective imminently. Additional details regarding the reverse stock split will be announced in the coming days. “The Company’s shareholders have already approved a reverse stock split, which is expected within the next few weeks, as part of our plan to regain compliance with the Minimum Bid Price Rule,” said Clearmind’s Chief Executive Officer Dr. Adi Zuloff-Shani. “We are looking forward to updating our shareholders regarding the Company’s compliance with the Minimum Bid Price Rule soon”.공시 • Nov 10Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League UniversitiesClearmind Medicine Inc. announced that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. Clearmind's flagship treatment is focused on AUD, which is an extremely common and devastating condition. The addiction varies from mild to acute and describes a person's inability to control their alcohol consumption, despite negative health, social and occupational consequences. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. Patients will also be monitored for their depression symptoms.Johns Hopkins University School of Medicine is the second US-based medical site to join the Company's clinical trial. The first US-based site was Yale School of Medicine'sDepartment of Psychiatry. The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in multiple human clinical trials. In Clearmind's phase I/IIa trial, CM-CMND-001, the primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and cravings, in individuals with moderate-to-severe AUD. Depression symptoms will also be evaluated as an exploratory endpoint.공시 • Oct 10Clearmind Medicine Inc. announced that it expects to receive $2.25 million in fundingClearmind Medicine Inc. announced a private placement to issue 7,500,000 common shares and 7,500,000 pre-funded warrants for the gross proceeds of $2,250,000 on October 9, 2023. These common warrants are immediately exercisable with an exercise price of $0.30 per common share, valid for five years from the issuance date. The transaction is subject to general shareholders of 8th Annual Dawson James Conference which is about to be held on October 12, 2023.공시 • Aug 24Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023.공시 • Aug 02SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.SSciSparc Ltd. announced that as part of its ongoing collaboration with Clearmind Medicine Inc. a patent application for the treatment of dyskinesia was filed by Clearmind, a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems. The provisional patent application was filed with the United States Patent and Trademark Office. This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.yskinesia is a category of movement disorders that are characterized by abnormal involuntary movements and may manifest as chorea (ir regular, involuntary movements of the body, especially the face and extremities) or dystonia (disorder or lack of muscle tonicity). Rapid, non-rhythmic, abnormal movements can appear in a host of commonly co-occurring conditions, including Tourette Syndrome and transient tic disorder, as well as during withdrawal from alcohol and other substances. This patent prospect corresponds well with SciSparc's robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.공시 • Jul 12Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment of Dr. Fatima Cody Stanford, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, to its Scientific Advisory Board. Dr. Stanford brings extensive expertise in the treatment of obesity, making her a valuable addition to Clearmind’s mission of transforming the treatment landscape for obesity by advancing MEAI as a potential treatment. Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker. Her extensive academic background includes a Bachelor of Science and Master of Public Health from Emory University, a MD from the Medical College of Georgia School of Medicine, a Masters of Public Administration from the Harvard Kennedy School of Government and a MBA from the Quantic School of Business and Technology. Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field. With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally. Her unique perspective and multidisciplinary approach are aligned with Clearmind Medicine’s vision to develop innovative treatments for addiction and address the underlying causes, including obesity.공시 • May 24Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use DisorderClearmind Medicine Inc. announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD"). Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial. The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse. She joined the Yale School of Medicine in 2018 as an Assistant Professor of Psychiatry, after completing her psychiatry residency at Mount Sinai Beth Israel and her addiction psychiatry fellowship at Mount Sinai West’s Icahn School of Medicine in New York. Clearmind recently announced it had been granted approval by the Ethics Committee (equivalent of an institutional review board) of Israel’s IMCA center for the Phase I/IIa clinical trial of CMND-100. The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. The primary end-point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and in those with AUD. The secondary end-point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe AUD.공시 • May 22Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price NotificationOn May 19, 2023, Clearmind Medicine Inc. announced that it has received a written notice (the ‘Notice’) from the Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice does not immediately affect the Company's Nasdaq listing or the trading of its ordinary shares. During the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol ‘CMND’. According to the Notice, the Company has until November 13, 2023, to regain compliance with the minimum bid price requirement. The company can regain compliance if, at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.공시 • May 13Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use DisorderClearmind Medicine Inc. has received Ethics Committee approval for its CM- CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD") at Israel's IMCA center. CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat GanThe company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites. The primary end point of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those withAUD. The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving, in individuals with moderate-to-severe AUD. Oral capsules will be administered once daily, for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.The Ethics Committee (which is the European and Israeli equivalent of the Institutional Review Board (IRB)), of the IMCA center, operating under the Declaration of Helsinki regulations and other international conventions concerning medical experiments on humans, is designated to authorize, review and monitor medical research and trials involving human subjects. The committee reviews research protocols and related materials (such as informed consent documents and investigator brochures) to ensure protection of the rights and welfare of the participants.공시 • May 09Clearmind Medicine Inc. Announces Board AppointmentsClearmind Medicine Inc. has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is also a member of the Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, served as president of the International Cannabinoid Research Society, and was a postdoctoral fellow at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH.공시 • Feb 16Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark OfficeClearmind Medicine Inc. announced that it has filed three provisional patent applications with the United States Patent and Trademark Office as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and SciSparc's Palmitoylethanolamide, the active ingredient of its proprietary CannAmide. SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. These new patent applications demonstrate Clearmind’s corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders waiting for transformative medicines by developing treatments that potentially may offer synergy, increased efficacy, and safety while reducing cost. Clearmind has a broad IP footprint in the psychedelic space with 23 patents in seven patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.공시 • Feb 01Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based CompoundClearmind Medicine Inc. announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial") resulted in positive outcomes in relation to treating Major Depressive Disorder (“MDD”). The trial evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression. The purpose of this trial was to determine 2-FDCK's effect on the motivational state of rodents as a treatment for depressive behavior and to test 2-FDCK as a potential novel long-term pharmacological psychoactive treatment for MDD. In the trial, the Flinders Sensitive Line (“FSL”) rat, an animal model of depression, were treated either by Ketamine or 2-FDCK for 14 consecutive days. The results indicated high potential safely treating both acute and chronic depression, compared to Ketamine that is used now for treating depression. The results suggest that there is a superior effect of 2-FDCK vs. Ketamine on the depressive-like behavior of the FSL animal model: Both Ketamine and 2-FDCK affected depressive-like symptoms. However, the effect was longer lasting when using a chronic treatment paradigm, only for 2-FDCK.공시 • Jan 18SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction TreatmentSciSparc Ltd. announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY). The results are in connection with the ongoing collaboration between the Company and Clearmind and the provisional patent application for treating cocaine addiction with Clearmind, based on SciSparc’s CannAmide™’s active ingredient Palmitoylethanolamide and Clearmind’s MEAI. The patent application was submitted to the United States Patent and Trademark Office in June 2022. The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced on August 24, 2022, Clearmind's proprietary MEAI at a dose of 5mg/kg, may be effective in the treatment of cocaine addiction by decreased craving for cocaine. The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system.공시 • Jan 12Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical TrialClearmind Medicine Inc. announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.공시 • Jan 10Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use DisorderClearmind Medicine Inc. has announced the first agreement to conduct its first- in-human clinical trial using its MEAI-based CMND-100 compound aimed at treating alcohol use disorder. The agreement was signed with the Phase I/II unit at the IMCA center in Ramat Gan, Israel. The trial will be led by Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specializations include cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders.공시 • Jan 06Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical TrialClearmind Medicine Inc. announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group. Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.공시 • Dec 15Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100Clearmind Medicine Inc. announced that it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at treating alcohol use disorder (AUD), in preparation for its first in-human clinical trial. An Investigational New Drug (IND) application is required by the U.S. Food and Drug Administration (FDA) before commencing clinical studies in humans may initiate. The company is in the process of preparing the IND for its submission to the FDA and the Israeli Ministry of Health. As part of this year-long process, the company preformed pharmacology, pharmacokinetics, and toxicology assessments on the MEAI-based compound. Previous pre-clinical studies using MEAI demonstrated a high safety profile and indications of a significant dose-dependent effect reducing alcohol consumption in treated animals. CMND-100, which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need. AUD is a chronic relapsing brain disorder characterized by impaired ability to control alcohol use despite negative social, occupational, and health consequences. One of the world’s gravest health problems, AUD costs the United States alone an estimated $250 billion each year, and is the third leading preventable cause of death in the country. CMND-100 is assumed to suppress the decision to consume more alcohol by potentially innervating neural pathways associated with the 5-HT1A receptor that lead to “sensible behavior.” Clearmind’s intellectual property portfolio includes issued patents in the United States, Europe, China and India covering, among other, the use of CMND-100 in treating AUD.공시 • Nov 24Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical TrialClearmind Medicine Inc. announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100. The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD). Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound. The Company previously announce that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development of CMND-100.공시 • Nov 16Clearmind Medicine Inc. Common Shares Deleted from OTC EquityClearmind Medicine Inc. Common Shares has been deleted from OTC Equity effective from November 15, 2022, due to Market Center Change Listed on NASDAQ.Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Chairman Amitay Weiss is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Nov 11+ 1 more updateClearmind Applies for Patent to Treat Obesity and Metabolic SyndromeClearmind Medicine Inc. announced it has filed a provisional patent application related to metabolic syndromes including obesity. The patent application is another result of the company's ongoing collaboration with SciSparc Ltd. a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem. The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmideTM, which is used for treating obesity and its related metabolic disorders.공시 • Oct 29Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022.공시 • Aug 25Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction TreatmentClearmind Medicine Inc. announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning. In the present trial, animals were catheterized and trained to self-administer cocaine. After the establishment of the addiction model, rats underwent an extinction phase where no cocaine was administered and MEAI was given to the test group. Finally, a relapse phase was carried out where the addicted rats were reminded of the drug with a single administration and then the animals were returned to the self-administration habitat, without receiving the drug. The assumption is that the more an animal yearns to receive the drug, the more it will press on the active pedal. The results identified a sub-group within the study, in a non-biased manner and with high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine, as compared to non-treated control group. This sub-group, representing 60% of animals, showed very high response, within the group and across the board. This pattern of results aligns with a previous Clearmind study which tested the conditioned place-preference paradigm, where similar sub-population group was identified in the context of cocaine preference. This research demonstrates again MEAI’s unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment.공시 • Jun 22Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine. A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystal’s work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine. Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago and the Yale University School of Medicine. Among many other positions he holds or has held, Dr. Krystal is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=12.1). He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.공시 • Jun 17Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as DirectorClearmind Medicine Inc. announced that Mr. Oded Gilboa left his role as a director of the company.공시 • Jun 16Clearmind Medicine Inc. Announces CFO ChangesClearmind Medicine Inc. announced the appointment of Mr. Alan Rootenberg as Chief Financial Officer, effective June 14, 2022 replacing Mr. Oded Gilboa as CFO.공시 • Jun 11+ 1 more updateClearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge BehaviorsClearmind Medicine Inc. announced the filing of a provisional patent application, related to a psychedelic combination therapy treating binge behaviors that results from its recently launched collaboration with SciSparc Ltd. SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent application refers to the combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addictions and binge behaviors with SciSparc's CannAmideTM. The patent application followed a successful pre-clinical study that showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmideTM treatment at the lower, sub-effective MEAI dose. Initial results of the pre-clinical, on mice, study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmideTM in addition to MEAI at a dose of 20 mg/kg, again compared to consumption before treatment. The mice were provided with 20% alcohol solution for 24 hours three times a week for seven weeks, and were treated every day with MEAI or the combination of MEAI and CannAmideTM during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; and water consumption was measured similarly in parallel.공시 • Jun 08Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction TreatmentClearmind Medicine Inc. announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference model. Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study. The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.공시 • Jun 03+ 1 more updateClearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction TreatmentClearmind Medicine Inc. announced it has filed a provisional patent application related to cocaine addiction. The move results from the company’s recently launched collaboration with SciSparc Ltd. The patent application refers to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide. The two companies plan to pursue a pre-clinical trial to examine the effect of the combination treatment as an anti-reward agent for treating cocaine addiction. Cocaine addiction in the United States peaked in the 1990s, and the current estimates by the National Institute on Drug Abuse claim at least 1.3 million Americans are addicted to cocaine. Annually, these users go to the hospital more than 350,000 times and account for 54% of drug-related incarcerations in federal jails and prisons, according to recent statistics from the U. S. Department of Justice. In addition, cocaine is either suspected or confirmed as the cause for nearly 16,000 overdose deaths in the United States each year. It’s at least a contributing factor in many more deaths, usually from violence, associated medical conditions or other health impacts of the user’s lifestyle.공시 • May 26Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination TreatmentClearmind Medicine Inc. announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind's proprietary psychedelic molecule MEAI and SciSparc's CannAmide™ for treating alcohol consumption. Earlier trials successfully showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in mice, with an additional significant effect achieved when combining CannAmide™ with a lower sub-effective MEAI dose. These positive results follow previously announced results showing that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p<0.01) compared to consumption before treatment. A histopathology assessment was conducted to determine safety of the proprietary combination of MEAI and CannAmide vs. control (mice that were not exposed to alcohol). Several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) were harvested from all experiment groups (n=3-5 per group) and evaluated for impairment. The severity of impairments was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). Results indicated a high safety profile of the combination treatment with no treatment-related changes observed.공시 • May 20Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol ConsumptionClearmind Medicine Inc. announced positive safety results of its proprietary molecule, MEAI, to treat alcohol abuse. To evaluate the efficacy and safety of its psychedelic-derived treatment, Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks. The groups were then given varying daily doses of the new treatment, with intermittent access to alcohol and water. After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving the treatment. The control group showed no statistical significant reduction.공시 • May 12SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge BehaviorsSciSparc Ltd. announced that its recently launched collaboration with Clearmind Medicine Inc. resulted in the filing of a provisional patent application related to a psychedelic combination therapy treating numerous binge behaviors. The patent application refers to the combination of SciSparc's CannAmide™ with Clearmind's MEAI, an innovative proprietary psychedelic treatment for addictions. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose. Initial results of the pre-clinical animal study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg and compared to consumption before treatment. The mice were provided with 20% alcohol solution, for 24 hours, three times a week, for seven weeks, and were treated every day with MEAI or MEAI/CannAmide™ during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly in parallel.공시 • May 10Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment of two new members to its Scientific Advisory Board (“SAB”). Prof. Christian G. Schütz MD PhD MPH FRCPC, of the University of British Columbia, Canada and Prof. Mark Weiser, MD, Chairman of Dept of Psychiatry at Sackler School of Medicine, and head of the Psychiatric Division at Sheba Medical- Center, Israel. Prof. Schütz, an Associate Professor at the Department of Psychiatry in the university’s Faculty of Medicine, focuses on clinical interventions and health service in substance use disorders and dual diagnoses (mental and substance use disorders), as well as neurobiological and neurocognitive aspects of impulsive decision-making. His main research focuses on understanding mechanisms of relapse and impulsive decision-making to improve treatment of addiction and concurrent disorders. He has published over 100 research articles and a dozen chapters. Prof. Weiser, head of the Psychiatric Division at Sheba Medical Hospital, specializes, among others, in cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Amitay Weiss is the most experienced director on the board, commencing their role in 2019. Independent Director Yehonatan Shachar was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Feb 09Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.Clearmind Medicine Inc. announced a private placement of 1,987,344 units at a subscription price of CAD 0.80 per unit for gross proceeds of CAD 1,589,875 on February 8, 2022. The transaction will include participation from Medigus Ltd. Each unit is comprised of one common share of the company and one common share purchase warrant exercisable into one additional common share at a price per common share of CAD 2, exercisable for a period of 18 months from issuance. Of the gross proceeds, approximately CAD 960,000 will be paid for in cash and approximately CAD 640,000 of the gross proceeds will be satisfied through the issuance to the company of that number of American Depository Shares of Medigus Ltd. arrived at by dividing the share exchange proceeds by $1.20.분석 기사 • Nov 10We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...공시 • Jul 01Clearmind Medicine Inc. announced that it has received CAD 6.225 million in fundingOn June 30, 2021, Clearmind Medicine Inc. closed the transaction. Each Warrant being exercisable to acquire one additional common share of the company at an exercise price of CAD 1.25 per Warrant Share until December 30,2022. All securities issued are subject to a statutory hold period,expiring onOctober 31, 2021, in accordance with applicable securities legislation. The Company paid finder's fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds.공시 • May 28Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in fundingClearmind Medicine Inc. (CNSX:CMND) announced a non-brokered private placement of a minimum of 5,000,000 units and a maximum of 8,000,000 units at a price of CAD 0.75 per unit for gross proceeds of minimum CAD 3,750,000 up to a maximum gross proceeds of CAD 6,000,000 on May 27, 2021. Each unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase a common share at a price of CAD 1.25 per warrant for a period of 18 months from the closing. The transaction may include participation from insiders of the company in an amount equal to 20%. The securities issued will be subject to hold period of four months and one day from issuance. The company expects to pay finder's fee payable in cash, of up to 10% of the gross proceeds or alternatively combination of cash in an amount of 5% of gross proceeds and finder warrants equal to 5% of units sold. Each finder warrants will be exercisable into common share at an exercise price of CAD 1 per share for a period of 18 months following the closing of the transaction. The transaction is expected to close on or about June 15, 2021.주주 수익률CMNDCA PharmaceuticalsCA 시장7D-14.9%-3.3%1.1%1Y-98.8%48.1%29.6%전체 주주 수익률 보기수익률 대 산업: CMND은 지난 1년 동안 48.1%의 수익을 기록한 Canadian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: CMND은 지난 1년 동안 29.6%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is CMND's price volatile compared to industry and market?CMND volatilityCMND Average Weekly Movement36.1%Pharmaceuticals Industry Average Movement10.0%Market Average Movement9.6%10% most volatile stocks in CA Market16.8%10% least volatile stocks in CA Market3.7%안정적인 주가: CMND의 주가는 지난 3개월 동안 Canadian 시장보다 변동성이 컸습니다.시간에 따른 변동성: CMND의 주간 변동성은 지난 1년간 30%에서 36%로 증가했습니다.회사 소개설립직원 수CEO웹사이트2017n/aAdi Zuloff-Shaniwww.clearmindmedicine.com더 보기Clearmind Medicine Inc. 기초 지표 요약Clearmind Medicine의 순이익과 매출은 시가총액과 어떻게 비교됩니까?CMND 기초 통계시가총액CA$5.07m순이익 (TTM)-CA$11.68m매출 (TTM)n/a0.0x주가매출비율(P/S)-0.4x주가수익비율(P/E)CMND는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표CMND 손익계산서 (TTM)매출US$0매출원가US$0총이익US$0기타 비용US$8.62m순이익-US$8.62m최근 보고된 실적Oct 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)-2.72총이익률0.00%순이익률0.00%부채/자본 비율0%CMND의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/03/17 10:45종가2024/03/15 00:00수익2023/10/31연간 수익2023/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Clearmind Medicine Inc.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 06Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentClearmind Medicine Inc. announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind's successful collaboration with SciSparc Ltd. ("SciSparc"), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-AcylethanOLamines family, including Palmitoylethanolamide.
공시 • Jan 02Clearmind Medicine Inc. Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeClearmind Medicine Inc. announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, Hong Kong and now Macau.
공시 • Dec 25Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical TrialClearmind Medicine Inc. announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100. The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline.
공시 • Nov 21Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025.
공시 • Sep 17Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyClearmind Medicine Inc. announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
공시 • Aug 30+ 1 more updateClearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination TreatmentClearmind Medicine Inc. announced the publication of its patent application under the international Patent Cooperation Treaty ("PCT") for innovative combinations of Ketamine and N-Acylethanolamines. The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. ("SciSparc"), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders. As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc's Palmitoylethanolamide ("PEA") with Clearmind's innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions, promoting weight loss and addressing mental health disorders. Furthermore, the two companies are jointly exploring new treatments based on different psychedelic molecules and PEA. To date, 13 patents related to this collaboration have been filled with the U.S. Patent and Trademark Office, as well as several other global jurisdictions. In 2019, the U.S. Food & Drug Administration (the "FDA") approved a ketamine derivative as a nasal spray medication for use in adult patients. It is specifically intended to treat depression in patients that have not responded to other treatments and to alleviate depressive symptoms in individuals with major depressive disorder (MDD) who are experiencing suicidal thoughts or exhibiting suicidal behavior. The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur. Ketamine was approved by the FDA for use under close supervision due to its associated side effects, including the risk of abuse and psychological as well as physical dependence. The ultimate goal is to provide patients with safe and effective treatments that offer t therapeutic benefits, while minimizing adverse effects. The company believe that the collaboration with SciSparc could lead to such solutions.
공시 • Jan 06Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentClearmind Medicine Inc. announced the publication of a European patent application with the European Patent office for its innovative combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent application refers to Clearmind's successful collaboration with SciSparc Ltd. ("SciSparc"), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-AcylethanOLamines family, including Palmitoylethanolamide.
공시 • Jan 02Clearmind Medicine Inc. Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeClearmind Medicine Inc. announced advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, further strengthens Clearmind's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families, with patents granted in major jurisdictions such as the US, Europe, China, India, Hong Kong and now Macau.
공시 • Dec 25Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical TrialClearmind Medicine Inc. announced it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine’s Department of Psychiatry by Dr. Anahita Bassir Nia, MD, an expert in psychiatry and addiction medicine. This milestone marks a significant step forward in Clearmind’s FDA-regulated clinical program, further expanding the multi-site trial to evaluate the safety, tolerability and efficacy of its proprietary investigational drug, CMND-100. The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the advancement of CMND-100 through the clinical pipeline.
공시 • Nov 21Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025.
공시 • Sep 17Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapyClearmind Medicine Inc. announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
공시 • Aug 30+ 1 more updateClearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination TreatmentClearmind Medicine Inc. announced the publication of its patent application under the international Patent Cooperation Treaty ("PCT") for innovative combinations of Ketamine and N-Acylethanolamines. The patent application was filed as a result of the Company's continuous collaboration with SciSparc Ltd. ("SciSparc"), a specialized pharmaceutical company in the clinical trial phase, dedicated to creating treatments for central nervous system disorders. As part of the collaboration, the two companies are researching combination therapies that integrate SciSparc's Palmitoylethanolamide ("PEA") with Clearmind's innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI), aimed at treating addictions, promoting weight loss and addressing mental health disorders. Furthermore, the two companies are jointly exploring new treatments based on different psychedelic molecules and PEA. To date, 13 patents related to this collaboration have been filled with the U.S. Patent and Trademark Office, as well as several other global jurisdictions. In 2019, the U.S. Food & Drug Administration (the "FDA") approved a ketamine derivative as a nasal spray medication for use in adult patients. It is specifically intended to treat depression in patients that have not responded to other treatments and to alleviate depressive symptoms in individuals with major depressive disorder (MDD) who are experiencing suicidal thoughts or exhibiting suicidal behavior. The approved treatment comes with strict usage guidelines. It must be administered only at certified medical facilities and used alongside an antidepressant medication. After receiving a dose, patients are required to remain at the facility for a two-hour observation period. This allows healthcare providers to monitor for any potentially serious side effects that may occur. Ketamine was approved by the FDA for use under close supervision due to its associated side effects, including the risk of abuse and psychological as well as physical dependence. The ultimate goal is to provide patients with safe and effective treatments that offer t therapeutic benefits, while minimizing adverse effects. The company believe that the collaboration with SciSparc could lead to such solutions.
공시 • Aug 22Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior TreatmentClearmind Medicine Inc. announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program. The approved patent claims cover, among other things, a method of regulating the consumption of alcoholic beverages and a method of controlling binge behavior through the administration of an amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the Company's innovative psychedelic molecule. This latest patent further bolsters Clearmind’s extensive intellectual property portfolio in the psychedelic sector, which now includes 29 granted patents across 19 patent families, with protections secured in key jurisdictions such as the U.S., Europe, China, and India.
공시 • Aug 07Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss DrugClearmind Medicine Inc. announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include: Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. Improved Metabolism: MEAI significantly improved glycemic control by reducing hyperglycemia, glucose intolerance and hyperinsulinemia, highlighting its therapeutic potential in regulating glucose metabolism. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels, mainly through inhibiting new lipid synthesis and reducing fat accumulation. Increased Energy Expenditure: MEAI increased energy expenditure and fat utilization while maintaining a similar food consumption. Activity: MEAI increased activity-specific energy expenditure without overstimulation supporting its potential to impact energy balance. These findings are based on the results from Clearmind Medicine’s study aimed to investigate the ability of MEAI to modulate metabolism and counteract obesity. This comprehensive study was published in ACS Pharmacology and Translational Science.
공시 • Jul 16Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossClearmind Medicine Inc. announced that it has submitted an additional patent application with the United States Patent and Trademark Office ("USPTO"), as part of its ongoing collaborations with SciSparc Ltd. ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with invented with Prof. Joseph Tam from the Hebrew University's technology transfer company, Yissum. The patent application refers to the novel proprietary composition of Clearmind's MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide ("PEA"), the active ingredient of SciSparc's proprietary CannAmide™, for treating metabolic syndrome and obesity. According to the 2017-2020 data from the National Health and Nutrition examination Survey (NHANES) database, the Centers for Disease Control and Prevention (CDC) reported that among adults aged 20 and over, the prevalence of obesity was 41.9%. According to Emergen Research, the global obesity treatment market size was valued at $15 billion in 2022 and is expected to register a rapid revenue CAGR of 10.0% during the forecast period of 2023 to 2032. Rising prevalence of obesity and technological advancements in weight loss equipment are key factors driving market revenue growth. Overall, as part of the collaboration with SciSparc, twelve other patent applications have been filed by Clearmind with the USPTO for various proprietary compositions, including the composition of SciSparc's PEA with Clearmind's MEAI compounds for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
공시 • May 11Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductClearmind Medicine Inc. announced advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed most of the pre-clinical studies required for a novel-food application submission according to novel foods and food additives legislation and regulations accepted in many jurisdictions worldwide. Clearmind’s alcohol substitute was granted patents in the U.S., India and Europe. This project is being led by former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, serving as an Executive Special Advisor to the Company.
공시 • Apr 10Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersClearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.
공시 • Mar 27Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating DepressionClearmind Medicine Inc. announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression. This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”). According to the ResearchAndMarkets.com, the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034. Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s PEA with Clearmind’s MEAI compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
공시 • Mar 15Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities ExchangeClearmind Medicine Inc. announced that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on the NASDAQ under the symbol CMND. The company believes that the trading volume of its shares on the CSE no longer justifies the expenses and administrative efforts required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its common shares on the NASDAQ, and ultimately benefit the long-term liquidity and shareholder value of the company. It is anticipated that, effective as at the close of trading on March 14, 2024, Clearmind’s common shares will no longer be listed and posted for trading on the CSE. Following delisting from the CSE, Clearmind’s shareholders can trade their common shares through their brokers on NASDAQ.
공시 • Mar 14Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical TrialClearmind Medicine Inc. announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trial, at the Yale School of Medicine’s Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol.
공시 • Feb 23Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderClearmind Medicine Inc. announced it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsules. The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States for the phase I/IIa clinical trials, at theale School of Medicine's Department of Psychiatry and the Johns Hopkins University School of Medicine. The primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in Healthy subjects and those with AUD. The secondary endpoint is to evaluate preliminary efficacy of CMND-100 in reduction of drinking patterns and cravings in individuals with moderate-to-severe AUD. Oral capsules will be administered and subjects treated by these oral capsules will report their drinking patterns and cravings for alcohol during the clinical trial. The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience. MEAI was found to interact with the serotonergic receptors 5-HT1a and 5-HT2a. The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence. MEAI was also found to interact with the alpha-2-adrenergic receptors a2A, a2B and a2C, as well as the plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). These receptors and transporters are believed to participate in mediating alcohol drinking behavior and could constitute important molecular targets for interventions that target drugs subject to abuse, such as alcohol.
공시 • Feb 06Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property AdministrationClearmind Medicine Inc. announced that it has been granted divisional patent approval by the China National Intellectual Property Administration. The granting of this latest patent establishes both the company's patent protection around its molecule as well as its extensive IP protection in the psychedelic space. Clearmind's IP portfolio consists of fifteen utility patent families, including patents and applications having method of use and composition of matter claims which includes 24 pending patent applications and 27 granted patents in major jurisdictions such as the US, Europe, China, and India. MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and exerts a slight euphoric, alcohol-like experience with potential to change the lives of millions who struggle to drink in moderation. Clearmind's MEAI-based treatment focuses on Alcohol Use Disorder, which is incredibly common. It varies from mild to excessive and is characterized by a person's inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Clearmind'sMEAI may also be used to treat binge drinking, which can be a deadly addiction for some.
공시 • Jan 17Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 1,500,000 Price\Range: CAD 1.6 Discount Per Security: CAD 0.128 Security Name: Pre-funded Warrants Security Type: Equity Warrant Securities Offered: 1,500,000 Transaction Features: Registered Direct Offering
공시 • Jan 11+ 1 more updateClearmind Medicine Inc. has filed a Follow-on Equity Offering.Clearmind Medicine Inc. has filed a Follow-on Equity Offering. Security Name: Common Shares Security Type: Common Stock Security Name: Pre-funded Warrants Security Type: Equity Warrant Transaction Features: Registered Direct Offering
공시 • Dec 15Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing StandardsClearmind Medicine Inc. announced that on December 12, 2023 it received a formal notification from The Nasdaq Stock Market LLC ('Nasdaq') that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company's common shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed. As a result, the scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel requested by the Company to stay the suspension of the Company’s securities from Nasdaq was canceled. The Company is now in compliance with all applicable listing standards and its common shares will continue to be listed and traded on Nasdaq.
공시 • Dec 03Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical TrialSciSparc Ltd. announced earlier this week successful results from a pre-clinical trial performed by Professor Joseph Tam from The Hebrew University of Jerusalem. The trial was conducted as part of the collaboration between SciSparc and Clearmind Medicine Inc. a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide™, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression (the “Combination Treatment”). The goal of the trial was to identify the optimal dosage for the Combination Treatment and, in turn, observe the safety and impact thereof on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a meaningful degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the Combination Treatment, with the most prominent effects observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated: The administered treatment exhibited a meaningful degree of tolerance, leaving the viability of the mice unaffected across all experimental groups. Combining MEAI and PEA, particularly at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. The changed rates of oxygen consumption and carbon dioxide emission indicate increases in the metabolic process and fat burn. A notable reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted particularly at 20 and 10 mg/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.
공시 • Nov 29Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based TreatmentClearmind Medicine Inc. announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem. The treatment used in the trial combined Clearmind's MEAI, a novel proprietary psychedelic treatment for various addiction, obesity and metabolic disorders and depression, and SciSparc's Palmitoylethanolamide (PEA), which is an anti-inflammatory agent and the active ingredient of its proprietary CannAmide™?. The goal of the trial was to identify the optimal dosage for their combination, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behavior. Fourteen different treatment groups were created (for a total of 84 animals) receiving single treatment doses ranging from 40, 20, 10, 5, 1, to 0.5 mg/kg of MEAI with or without a constant PEA dose of 25 mg/kg. MEAI administration exhibited a remarkable degree of tolerance, leaving the animals' viability unaffected across all experimental groups. Similar results were also observed in groups treated by the combination of MEAI and PEA with the most prominent effects being observed when combining MEAI and PEA, particularly at 20 and 10 mg/kg. Results indicated that: The administered treatment exhibited a remarkable degree of tolerance., leaving the mice' viability unaffected across all experimental group. Combining MEAI and PEA, especially at 20 and 10 mg/kg, led to increased oxygen consumption and carbon dioxide emission, coupled with elevated energy expenditure and fat oxidation. oxygen consumption and carbon dioxide emission indicates increase in metabolic process and fat burn. A striking reduction in food consumption (appetite) and meal sizes was also observed, primarily at 40 and 20 mg/kg of MEAI. Slight elevations in carbohydrate oxidation were noted, particularly at 20 and 10 u/kg. At 40 and 20 mg/kg significant reductions in ambulation was noted, without affecting voluntary activity.
공시 • Nov 18Clearmind Medicine Announces Receipt of Nasdaq Delisting NoticeClearmind Medicine Inc. announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq"). The Company was notified that Nasdaq has determined to delist the Company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Company plans to appeal the Staff’s determination to a Hearings Panel (the “Panel”). A hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. As part of the plan to regain compliance with the Minimum Bid Price Rule, the Company intends to conduct a reverse stock split as soon as reasonably practicable, subject to applicable law and Nasdaq rules. On November 14th, the Company’s shareholders approved a reverse stock split, which the Company expects will be made effective imminently. Additional details regarding the reverse stock split will be announced in the coming days. “The Company’s shareholders have already approved a reverse stock split, which is expected within the next few weeks, as part of our plan to regain compliance with the Minimum Bid Price Rule,” said Clearmind’s Chief Executive Officer Dr. Adi Zuloff-Shani. “We are looking forward to updating our shareholders regarding the Company’s compliance with the Minimum Bid Price Rule soon”.
공시 • Nov 10Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League UniversitiesClearmind Medicine Inc. announced that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. Clearmind's flagship treatment is focused on AUD, which is an extremely common and devastating condition. The addiction varies from mild to acute and describes a person's inability to control their alcohol consumption, despite negative health, social and occupational consequences. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. Patients will also be monitored for their depression symptoms.Johns Hopkins University School of Medicine is the second US-based medical site to join the Company's clinical trial. The first US-based site was Yale School of Medicine'sDepartment of Psychiatry. The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in multiple human clinical trials. In Clearmind's phase I/IIa trial, CM-CMND-001, the primary endpoint of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary endpoint is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and cravings, in individuals with moderate-to-severe AUD. Depression symptoms will also be evaluated as an exploratory endpoint.
공시 • Oct 10Clearmind Medicine Inc. announced that it expects to receive $2.25 million in fundingClearmind Medicine Inc. announced a private placement to issue 7,500,000 common shares and 7,500,000 pre-funded warrants for the gross proceeds of $2,250,000 on October 9, 2023. These common warrants are immediately exercisable with an exercise price of $0.30 per common share, valid for five years from the issuance date. The transaction is subject to general shareholders of 8th Annual Dawson James Conference which is about to be held on October 12, 2023.
공시 • Aug 24Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023.
공시 • Aug 02SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.SSciSparc Ltd. announced that as part of its ongoing collaboration with Clearmind Medicine Inc. a patent application for the treatment of dyskinesia was filed by Clearmind, a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems. The provisional patent application was filed with the United States Patent and Trademark Office. This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.yskinesia is a category of movement disorders that are characterized by abnormal involuntary movements and may manifest as chorea (ir regular, involuntary movements of the body, especially the face and extremities) or dystonia (disorder or lack of muscle tonicity). Rapid, non-rhythmic, abnormal movements can appear in a host of commonly co-occurring conditions, including Tourette Syndrome and transient tic disorder, as well as during withdrawal from alcohol and other substances. This patent prospect corresponds well with SciSparc's robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
공시 • Jul 12Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment of Dr. Fatima Cody Stanford, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, to its Scientific Advisory Board. Dr. Stanford brings extensive expertise in the treatment of obesity, making her a valuable addition to Clearmind’s mission of transforming the treatment landscape for obesity by advancing MEAI as a potential treatment. Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker. Her extensive academic background includes a Bachelor of Science and Master of Public Health from Emory University, a MD from the Medical College of Georgia School of Medicine, a Masters of Public Administration from the Harvard Kennedy School of Government and a MBA from the Quantic School of Business and Technology. Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field. With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally. Her unique perspective and multidisciplinary approach are aligned with Clearmind Medicine’s vision to develop innovative treatments for addiction and address the underlying causes, including obesity.
공시 • May 24Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use DisorderClearmind Medicine Inc. announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD"). Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial. The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse. She joined the Yale School of Medicine in 2018 as an Assistant Professor of Psychiatry, after completing her psychiatry residency at Mount Sinai Beth Israel and her addiction psychiatry fellowship at Mount Sinai West’s Icahn School of Medicine in New York. Clearmind recently announced it had been granted approval by the Ethics Committee (equivalent of an institutional review board) of Israel’s IMCA center for the Phase I/IIa clinical trial of CMND-100. The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects. In the clinical trial, oral capsules will be administered once daily for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period. The primary end-point of the trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and in those with AUD. The secondary end-point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe AUD.
공시 • May 22Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price NotificationOn May 19, 2023, Clearmind Medicine Inc. announced that it has received a written notice (the ‘Notice’) from the Nasdaq Stock Market LLC (‘Nasdaq’) indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a grace period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice does not immediately affect the Company's Nasdaq listing or the trading of its ordinary shares. During the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol ‘CMND’. According to the Notice, the Company has until November 13, 2023, to regain compliance with the minimum bid price requirement. The company can regain compliance if, at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be closed. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
공시 • May 13Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use DisorderClearmind Medicine Inc. has received Ethics Committee approval for its CM- CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD") at Israel's IMCA center. CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat GanThe company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites. The primary end point of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those withAUD. The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving, in individuals with moderate-to-severe AUD. Oral capsules will be administered once daily, for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.The Ethics Committee (which is the European and Israeli equivalent of the Institutional Review Board (IRB)), of the IMCA center, operating under the Declaration of Helsinki regulations and other international conventions concerning medical experiments on humans, is designated to authorize, review and monitor medical research and trials involving human subjects. The committee reviews research protocols and related materials (such as informed consent documents and investigator brochures) to ensure protection of the rights and welfare of the participants.
공시 • May 09Clearmind Medicine Inc. Announces Board AppointmentsClearmind Medicine Inc. has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is also a member of the Harvey M. Krueger Family Center for Nanoscience and Nanotechnology, served as president of the International Cannabinoid Research Society, and was a postdoctoral fellow at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH.
공시 • Feb 16Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark OfficeClearmind Medicine Inc. announced that it has filed three provisional patent applications with the United States Patent and Trademark Office as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. The patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine and SciSparc's Palmitoylethanolamide, the active ingredient of its proprietary CannAmide. SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. These new patent applications demonstrate Clearmind’s corporate strategy to broaden the therapeutic psychedelic toolbox for patients with mental health disorders waiting for transformative medicines by developing treatments that potentially may offer synergy, increased efficacy, and safety while reducing cost. Clearmind has a broad IP footprint in the psychedelic space with 23 patents in seven patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
공시 • Feb 01Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based CompoundClearmind Medicine Inc. announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a new pre-clinical trial (the “trial") resulted in positive outcomes in relation to treating Major Depressive Disorder (“MDD”). The trial evaluated 2-Fluorodeschloroketamine’s (“2-FDCK”), an innovative analogue of Ketamine, of which the Company has a pending patent with the United States Patent and Trademark Office, for its use in treating depression including treatment resistant depression. The purpose of this trial was to determine 2-FDCK's effect on the motivational state of rodents as a treatment for depressive behavior and to test 2-FDCK as a potential novel long-term pharmacological psychoactive treatment for MDD. In the trial, the Flinders Sensitive Line (“FSL”) rat, an animal model of depression, were treated either by Ketamine or 2-FDCK for 14 consecutive days. The results indicated high potential safely treating both acute and chronic depression, compared to Ketamine that is used now for treating depression. The results suggest that there is a superior effect of 2-FDCK vs. Ketamine on the depressive-like behavior of the FSL animal model: Both Ketamine and 2-FDCK affected depressive-like symptoms. However, the effect was longer lasting when using a chronic treatment paradigm, only for 2-FDCK.
공시 • Jan 18SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction TreatmentSciSparc Ltd. announced additional positive pre-clinical results in ongoing series of research studies of treatment for cocaine using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY). The results are in connection with the ongoing collaboration between the Company and Clearmind and the provisional patent application for treating cocaine addiction with Clearmind, based on SciSparc’s CannAmide™’s active ingredient Palmitoylethanolamide and Clearmind’s MEAI. The patent application was submitted to the United States Patent and Trademark Office in June 2022. The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced on August 24, 2022, Clearmind's proprietary MEAI at a dose of 5mg/kg, may be effective in the treatment of cocaine addiction by decreased craving for cocaine. The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system.
공시 • Jan 12Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical TrialClearmind Medicine Inc. announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
공시 • Jan 10Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use DisorderClearmind Medicine Inc. has announced the first agreement to conduct its first- in-human clinical trial using its MEAI-based CMND-100 compound aimed at treating alcohol use disorder. The agreement was signed with the Phase I/II unit at the IMCA center in Ramat Gan, Israel. The trial will be led by Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specializations include cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders.
공시 • Jan 06Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical TrialClearmind Medicine Inc. announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI. The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group. Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
공시 • Dec 15Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100Clearmind Medicine Inc. announced that it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at treating alcohol use disorder (AUD), in preparation for its first in-human clinical trial. An Investigational New Drug (IND) application is required by the U.S. Food and Drug Administration (FDA) before commencing clinical studies in humans may initiate. The company is in the process of preparing the IND for its submission to the FDA and the Israeli Ministry of Health. As part of this year-long process, the company preformed pharmacology, pharmacokinetics, and toxicology assessments on the MEAI-based compound. Previous pre-clinical studies using MEAI demonstrated a high safety profile and indications of a significant dose-dependent effect reducing alcohol consumption in treated animals. CMND-100, which is Clearmind’s lead compound, is a novel psychedelic-derived drug candidate, exhibiting compelling evidence that suggests a significant reduction of desire to consume alcoholic beverages- addressing a global unmet need. AUD is a chronic relapsing brain disorder characterized by impaired ability to control alcohol use despite negative social, occupational, and health consequences. One of the world’s gravest health problems, AUD costs the United States alone an estimated $250 billion each year, and is the third leading preventable cause of death in the country. CMND-100 is assumed to suppress the decision to consume more alcohol by potentially innervating neural pathways associated with the 5-HT1A receptor that lead to “sensible behavior.” Clearmind’s intellectual property portfolio includes issued patents in the United States, Europe, China and India covering, among other, the use of CMND-100 in treating AUD.
공시 • Nov 24Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical TrialClearmind Medicine Inc. announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100. The produced batches will be used in the Company's upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD). Following MEAI's synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company's pre- clinical studies designed to evaluate the safety of its innovative compound. The Company previously announce that it completed a highly constructive Pre-Investigational New Drug Application ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the development of CMND-100.
공시 • Nov 16Clearmind Medicine Inc. Common Shares Deleted from OTC EquityClearmind Medicine Inc. Common Shares has been deleted from OTC Equity effective from November 15, 2022, due to Market Center Change Listed on NASDAQ.
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. Independent Chairman Amitay Weiss is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Nov 11+ 1 more updateClearmind Applies for Patent to Treat Obesity and Metabolic SyndromeClearmind Medicine Inc. announced it has filed a provisional patent application related to metabolic syndromes including obesity. The patent application is another result of the company's ongoing collaboration with SciSparc Ltd. a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem. The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmideTM, which is used for treating obesity and its related metabolic disorders.
공시 • Oct 29Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022.
공시 • Aug 25Clearmind Medicine Announces Additional Positive Pre-Clinical Results for Its Cocaine Addiction TreatmentClearmind Medicine Inc. announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning. In the present trial, animals were catheterized and trained to self-administer cocaine. After the establishment of the addiction model, rats underwent an extinction phase where no cocaine was administered and MEAI was given to the test group. Finally, a relapse phase was carried out where the addicted rats were reminded of the drug with a single administration and then the animals were returned to the self-administration habitat, without receiving the drug. The assumption is that the more an animal yearns to receive the drug, the more it will press on the active pedal. The results identified a sub-group within the study, in a non-biased manner and with high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine, as compared to non-treated control group. This sub-group, representing 60% of animals, showed very high response, within the group and across the board. This pattern of results aligns with a previous Clearmind study which tested the conditioned place-preference paradigm, where similar sub-population group was identified in the context of cocaine preference. This research demonstrates again MEAI’s unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment.
공시 • Jun 22Clearmind Medicine Inc. Appoints John Krystal to its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment to its Scientific Advisory Board of John Krystal, Chair of the Psychiatry Department at Yale University’s School of Medicine. A leading expert on alcoholism, post-traumatic stress disorder, schizophrenia, and depression, Dr. Krystal’s work links psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobiology and treatment of these disorders. He is best known for leading the discovery of the rapid antidepressant effects of ketamine. Dr. Krystal is a Professor of Translational Research; Psychiatry, Neuroscience, and Psychology; he chairs the Department of Psychiatry at Yale University; and he is Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago and the Yale University School of Medicine. Among many other positions he holds or has held, Dr. Krystal is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD, co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of Biological Psychiatry (IF=12.1). He is a member of the U.S. National Academy of Medicine and a Fellow of the American Association for the Advancement of Science.
공시 • Jun 17Clearmind Medicine Inc. Announces the Resignation of Oded Gilboa as DirectorClearmind Medicine Inc. announced that Mr. Oded Gilboa left his role as a director of the company.
공시 • Jun 16Clearmind Medicine Inc. Announces CFO ChangesClearmind Medicine Inc. announced the appointment of Mr. Alan Rootenberg as Chief Financial Officer, effective June 14, 2022 replacing Mr. Oded Gilboa as CFO.
공시 • Jun 11+ 1 more updateClearmind Medicine Inc. and SciSparc Ltd Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge BehaviorsClearmind Medicine Inc. announced the filing of a provisional patent application, related to a psychedelic combination therapy treating binge behaviors that results from its recently launched collaboration with SciSparc Ltd. SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The patent application refers to the combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addictions and binge behaviors with SciSparc's CannAmideTM. The patent application followed a successful pre-clinical study that showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmideTM treatment at the lower, sub-effective MEAI dose. Initial results of the pre-clinical, on mice, study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmideTM in addition to MEAI at a dose of 20 mg/kg, again compared to consumption before treatment. The mice were provided with 20% alcohol solution for 24 hours three times a week for seven weeks, and were treated every day with MEAI or the combination of MEAI and CannAmideTM during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; and water consumption was measured similarly in parallel.
공시 • Jun 08Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction TreatmentClearmind Medicine Inc. announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference model. Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study. The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.
공시 • Jun 03+ 1 more updateClearmind Medicine Inc. and Scisparc Collaboration Yields Another Patent Application for Cocaine Addiction TreatmentClearmind Medicine Inc. announced it has filed a provisional patent application related to cocaine addiction. The move results from the company’s recently launched collaboration with SciSparc Ltd. The patent application refers to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide. The two companies plan to pursue a pre-clinical trial to examine the effect of the combination treatment as an anti-reward agent for treating cocaine addiction. Cocaine addiction in the United States peaked in the 1990s, and the current estimates by the National Institute on Drug Abuse claim at least 1.3 million Americans are addicted to cocaine. Annually, these users go to the hospital more than 350,000 times and account for 54% of drug-related incarcerations in federal jails and prisons, according to recent statistics from the U. S. Department of Justice. In addition, cocaine is either suspected or confirmed as the cause for nearly 16,000 overdose deaths in the United States each year. It’s at least a contributing factor in many more deaths, usually from violence, associated medical conditions or other health impacts of the user’s lifestyle.
공시 • May 26Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination TreatmentClearmind Medicine Inc. announced positive safety profile results from its joint pre-clinical trial with SciSparc Ltd. The trial evaluated the proprietary combination of Clearmind's proprietary psychedelic molecule MEAI and SciSparc's CannAmide™ for treating alcohol consumption. Earlier trials successfully showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in mice, with an additional significant effect achieved when combining CannAmide™ with a lower sub-effective MEAI dose. These positive results follow previously announced results showing that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p<0.01) compared to consumption before treatment. A histopathology assessment was conducted to determine safety of the proprietary combination of MEAI and CannAmide vs. control (mice that were not exposed to alcohol). Several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) were harvested from all experiment groups (n=3-5 per group) and evaluated for impairment. The severity of impairments was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). Results indicated a high safety profile of the combination treatment with no treatment-related changes observed.
공시 • May 20Clearmind Medicine Inc. Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol ConsumptionClearmind Medicine Inc. announced positive safety results of its proprietary molecule, MEAI, to treat alcohol abuse. To evaluate the efficacy and safety of its psychedelic-derived treatment, Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks. The groups were then given varying daily doses of the new treatment, with intermittent access to alcohol and water. After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving the treatment. The control group showed no statistical significant reduction.
공시 • May 12SciSparc Ltd. and Clearmind Medicine Inc. Collaborations Yields New Patent Application for Psychedelic Combination Treatment for Binge BehaviorsSciSparc Ltd. announced that its recently launched collaboration with Clearmind Medicine Inc. resulted in the filing of a provisional patent application related to a psychedelic combination therapy treating numerous binge behaviors. The patent application refers to the combination of SciSparc's CannAmide™ with Clearmind's MEAI, an innovative proprietary psychedelic treatment for addictions. The patent application followed successful pre-clinical studies that showed a significant dose dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose. Initial results of the pre-clinical animal study showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and at higher doses (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg and compared to consumption before treatment. The mice were provided with 20% alcohol solution, for 24 hours, three times a week, for seven weeks, and were treated every day with MEAI or MEAI/CannAmide™ during the last two weeks of alcohol treatment. The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly in parallel.
공시 • May 10Clearmind Medicine Inc. Announces the Appointment of Two New Members to Its Scientific Advisory BoardClearmind Medicine Inc. announced the appointment of two new members to its Scientific Advisory Board (“SAB”). Prof. Christian G. Schütz MD PhD MPH FRCPC, of the University of British Columbia, Canada and Prof. Mark Weiser, MD, Chairman of Dept of Psychiatry at Sackler School of Medicine, and head of the Psychiatric Division at Sheba Medical- Center, Israel. Prof. Schütz, an Associate Professor at the Department of Psychiatry in the university’s Faculty of Medicine, focuses on clinical interventions and health service in substance use disorders and dual diagnoses (mental and substance use disorders), as well as neurobiological and neurocognitive aspects of impulsive decision-making. His main research focuses on understanding mechanisms of relapse and impulsive decision-making to improve treatment of addiction and concurrent disorders. He has published over 100 research articles and a dozen chapters. Prof. Weiser, head of the Psychiatric Division at Sheba Medical Hospital, specializes, among others, in cognitive impairment in persons with psychiatric disorders such as substance abuse, depression and personality disorders.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Amitay Weiss is the most experienced director on the board, commencing their role in 2019. Independent Director Yehonatan Shachar was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Feb 09Clearmind Medicine Inc. announced that it expects to receive CAD 0.96 million in funding from Medigus Ltd.Clearmind Medicine Inc. announced a private placement of 1,987,344 units at a subscription price of CAD 0.80 per unit for gross proceeds of CAD 1,589,875 on February 8, 2022. The transaction will include participation from Medigus Ltd. Each unit is comprised of one common share of the company and one common share purchase warrant exercisable into one additional common share at a price per common share of CAD 2, exercisable for a period of 18 months from issuance. Of the gross proceeds, approximately CAD 960,000 will be paid for in cash and approximately CAD 640,000 of the gross proceeds will be satisfied through the issuance to the company of that number of American Depository Shares of Medigus Ltd. arrived at by dividing the share exchange proceeds by $1.20.
분석 기사 • Nov 10We're Not Very Worried About Clearmind Medicine's (CSE:CMND) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
공시 • Jul 01Clearmind Medicine Inc. announced that it has received CAD 6.225 million in fundingOn June 30, 2021, Clearmind Medicine Inc. closed the transaction. Each Warrant being exercisable to acquire one additional common share of the company at an exercise price of CAD 1.25 per Warrant Share until December 30,2022. All securities issued are subject to a statutory hold period,expiring onOctober 31, 2021, in accordance with applicable securities legislation. The Company paid finder's fees in association with this financing, payable in cash, of up to 10% of the Gross Proceeds.
공시 • May 28Clearmind Medicine Inc. announced that it expects to receive CAD 6 million in fundingClearmind Medicine Inc. (CNSX:CMND) announced a non-brokered private placement of a minimum of 5,000,000 units and a maximum of 8,000,000 units at a price of CAD 0.75 per unit for gross proceeds of minimum CAD 3,750,000 up to a maximum gross proceeds of CAD 6,000,000 on May 27, 2021. Each unit consists of one common share and one common share purchase warrant. Each warrant will entitle the holder to purchase a common share at a price of CAD 1.25 per warrant for a period of 18 months from the closing. The transaction may include participation from insiders of the company in an amount equal to 20%. The securities issued will be subject to hold period of four months and one day from issuance. The company expects to pay finder's fee payable in cash, of up to 10% of the gross proceeds or alternatively combination of cash in an amount of 5% of gross proceeds and finder warrants equal to 5% of units sold. Each finder warrants will be exercisable into common share at an exercise price of CAD 1 per share for a period of 18 months following the closing of the transaction. The transaction is expected to close on or about June 15, 2021.
